Milacainide
Alternative Names: RO 229194Latest Information Update: 01 Apr 2008
Price :
$50 *
At a glance
- Originator Roche
- Developer Kissei Pharmaceutical; Roche
- Class Class I antiarrhythmics
- Mechanism of Action Sodium channel antagonists; Thromboxane A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 13 Oct 1998 RO 229194 is now called milacainide
- 09 Feb 1998 Phase-II clinical trials for Arrhythmias in Japan (IV)
- 09 Feb 1998 Phase-II clinical trials for Arrhythmias in Japan (PO)